Premium
Bone mineral status after treatment of malignant lymphoma in childhood and adolescence
Author(s) -
SALA A.,
TALSMA D.,
WEBBER C.,
POSGATE S.,
ATKINSON S.,
BARR R.
Publication year - 2007
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2006.00757.x
Subject(s) - medicine , bone mineral , osteopenia , osteoporosis , lymphoma , trab , gastroenterology , nuclear medicine , disease , graves' disease
The relationship between bone mineral mass and cumulative dose of corticosteroids (CDC) was investigated in 42 children and adolescents treated for Hodgkin disease (HD; n = 22) and non‐Hodgkin lymphoma (NHL; n = 20). The median age at the time of the study was 24.1 years for HD survivors and 14.1 years for NHL survivors. Dual‐energy X‐ray absorptiometry [bone mineral density of the lumbar spine (LS‐BMD) expressed as Z ‐scores] and peripheral quantitative computed tomography at the distal radius [trabecular volumetric BMD (vBMD‐trab)] were undertaken. Osteopenia ( Z ‐score < −1.00) was found in 9/22 patients with HD and 10/20 with NHL, while 34% (HD = 6, NHL = 8) had a vBMD‐trab below the normal range. The CDC correlated inversely with LS‐BMD Z ‐score ( r =−0.41, P = 0.007). There was a statistically significantly higher vBMD‐trab in patients who received low (1–4 g/m 2 ) compared with high (≥20 g/m 2 ) CDC ( P = 0.031). Treatment of malignant lymphoma with high CDC is a risk factor for development of osteopenia.